Manager TitleAgeSince
Chief Operating Officer - 2022-11-13
Director TitleAgeSince
Director/Board Member 61 2005-08-15
Chairman 67 2014-09-18
Director/Board Member 56 2008-06-04
Change 5-day change 1-year change 3-year change Capi.($)
-23.37%-37.69% - - 1.28M
+0.65%-3.36%+36.98%+60.50% 64.14B
+1.21%+2.94%+12.53%+84.36% 55.53B
+1.57%+1.72%+12.98%+105.14% 53.03B
+2.76%+0.87%+27.92%+55.07% 45.99B
+2.00%-3.39%+17.83%+119.04% 42.45B
+1.34%-2.86%+224.43%+914.08% 40.45B
+0.64%-3.95%+11.15%+45.57% 32.25B
-2.43%+42.61%+103.60%+90.11% 34.47B
-2.72%-0.44%+23.18%-10.77% 24.23B
Average -1.86%+4.08%+52.29%+162.57% 43.62B
Weighted average by Cap. +0.81%+3.49%+49.34%+160.53%
Logo 4SC AG
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Employees
14